To date, the TRial for Anti-B-Cell Therapy In patients with pSS (TRACTISS) is the largest multi-centre, placebo-controlled, phase-III trial with the administration of 2 cycles of RTX (or placebo) at baseline and 24 weeks, with the trial primary and secondary endpoints evaluated at 48 weeks.
This website allows to explore curated salivary gland RNA-seq data from the TRACTISS trial.
All the figures shown in this website can be downloaded in high, publication-ready resolution. To enable downloading please ask login credentials to Elena Pontarini (e.pontarini@qmul.ac.uk) or Elisabetta Sciacca (e.sciacca@qmul.ac.uk).
Pontarini et al. Serum and tissue biomarkers associated with CRESS and STAR response to B-cell targeted therapy
in TRACTISS trial of Sjogren's syndrome. Arthritis Rheumatol.2023
Sciacca, E., Cavallaro, G., Goldmann, K., & Lewis, M. (2023). TRial for Anti-B-Cell Therapy In Sjogren's Syndrome (TRACTISS): randomised clinical trial of Rituximab in pSS https://tractiss.hpc.qmul.ac.uk/
To date, the TRial for Anti-B-Cell Therapy In patients with pSS (TRACTISS)
is the largest multi-centre, placebo-controlled, phase-III trial with the
administration of 2 cycles of RTX (or placebo) at baseline and 24 weeks,
with the trial primary and secondary endpoints evaluated at 48 weeks.
This website acts as supplementary material for Pontarini et al. Serum and tissue biomarkers associated with CRESS and STAR response to B-cell targeted therapy in TRACTISS trial of Sjogren's syndrome. Arthritis Rheumatol.2023 [7].
It allows users to explore curated salivary gland RNA-seq data from the TRACTISS trial. Salivary gland biopsies were taken at baseline (Visit 4), week 16 (Visit 7), and week 48 (Visit 12) with accompanying clinical data.